CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $123.26B, higher than 95% of all stocks globally
- PositionProfit margin is 35.5%, higher than 95% of its Biotechnology peers (median 6%)
- Interpretations9 currently firing — 9
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
123.26BUSDvs all stocks (USD)
Trailing P/E
28.82xvs Biotechnology peers
Revenue (TTM)
12.22BUSDvs all stocks (USD)
Profit Margin
35.51%vs Biotechnology peers
Beta
0.2920xvs all stocks
52-Week Change
5.92%vs all stocks
Market Capitalization
123.26BUSDvs all stocks (USD)
Enterprise Value
118.00BUSDvs all stocks (USD)
Trailing P/E
28.82xvs Biotechnology peers
Forward P/E
22.68xvs Biotechnology peers
PEG Ratio
0.4716xPrice to Sales (TTM)
10.09xvs Biotechnology peers
Price to Book (MRQ)
6.38xvs Biotechnology peers
Enterprise to Revenue
9.66xvs Biotechnology peers
Enterprise to EBITDA
23.69xvs Biotechnology peers
Gross Margin
86.85%vs Biotechnology peers
Profit Margin
35.51%vs Biotechnology peers
Operating Margin
38.13%vs Biotechnology peers
Return on Assets (TTM)
12.14%vs Biotechnology peers
Return on Equity (TTM)
24.20%vs Biotechnology peers
Revenue (TTM)
12.22BUSDvs all stocks (USD)
Revenue per Share (TTM)
47.91USDUpdated Jul 19, 2026Quarterly Revenue Growth
7.80%vs Biotechnology peers
Gross Profit (TTM)
6.65BUSDvs all stocks (USD)
EBITDA (TTM)
5.26BUSDvs all stocks (USD)
Net Income (TTM)
4.34BUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
59.60%vs Biotechnology peers
Operating Cash Flow (TTM)
4.24BUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
2.78BUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
12.00BUSDFY2025 · Dec 31, 2025Cost of Goods Sold
1.65BUSDFY2025 · Dec 31, 2025Gross Profit
10.35BUSDFY2025 · Dec 31, 2025Operating Income
4.55BUSDvs all stocks (USD)
Pre-tax Income
4.64BUSDFY2025 · Dec 31, 2025Income Tax Expense
690.00MUSDFY2025 · Dec 31, 2025Net Income
3.95BUSDFY2025 · Dec 31, 2025EBIT
4.66BUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
5.25BUSDFY2025 · Dec 31, 2025Research & Development
4.04BUSDFY2025 · Dec 31, 2025Selling, General & Administrative
1.75BUSDFY2025 · Dec 31, 2025Non-operating Interest Income
490.90MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
13.30MUSDFY2025 · Dec 31, 2025EPS (Basic)
15.46USDFY2025 · Dec 31, 2025EPS (Diluted)
15.32USDFY2025 · Dec 31, 2025Basic Shares Outstanding
255.70MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
255.70MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
3.95BUSDFY2025 · Dec 31, 2025Operating Cash Flow
3.77BUSDFY2025 · Dec 31, 2025Free Cash Flow
3.33BUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
5.09BUSDFY2025 · Dec 31, 2025Income Tax Paid
1.57BUSDFY2025 · Dec 31, 2025Interest Paid
12.40MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
3.95BUSDFY2025 · Dec 31, 2025Depreciation & Amortization
209.80MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-510.80MUSDFY2025 · Dec 31, 2025Stock-based Compensation
685.90MUSDFY2025 · Dec 31, 2025Other Non-cash Items
113.40MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-347.30MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
36.80MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-375.70MUSDFY2025 · Dec 31, 2025Capital Expenditures
-437.60MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-6.40BUSDFY2025 · Dec 31, 2025Sale of Investments
5.91BUSDFY2025 · Dec 31, 2025Other Investing Activity
-24.70MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-945.40MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-5.40MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-2.39BUSDFY2025 · Dec 31, 2025Other Financing Charges
3.70MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-2.39BUSDFY2025 · Dec 31, 2025Shares Outstanding
254.16MSharesUpdated Jul 19, 2026Float Shares
253.07MSharesUpdated Jul 19, 2026Shares Short
4.94MSharesUpdated Jul 19, 2026Short Ratio
2.71daysvs all stocks
Short % of Shares Outstanding
2.20%vs all stocks
% Held by Insiders
0.20%vs all stocks
% Held by Institutions
99.34%vs all stocks
Total Cash (MRQ)
7.25BUSDvs all stocks (USD)
Total Cash per Share (MRQ)
28.55USDUpdated Jul 19, 2026Total Debt (MRQ)
1.99BUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1026xvs Biotechnology peers
Current Ratio (MRQ)
3.02xvs Biotechnology peers
Book Value per Share (MRQ)
76.18USDUpdated Jul 19, 2026Total Assets
25.64BUSDvs all stocks (USD)
Total Current Assets
11.20BUSDFY2025 · Dec 31, 2025Total Liabilities
6.98BUSDFY2025 · Dec 31, 2025Total Non-current Assets
14.44BUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
3.12BUSDFY2025 · Dec 31, 2025Total Current Liabilities
3.86BUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
5.08BUSDFY2025 · Dec 31, 2025Other Short-term Investments
1.52BUSDFY2025 · Dec 31, 2025Accounts Receivable
2.05BUSDFY2025 · Dec 31, 2025Inventory
1.69BUSDFY2025 · Dec 31, 2025Accounts Payable
461.70MUSDFY2025 · Dec 31, 2025Short-term Debt
77.30MUSDFY2025 · Dec 31, 2025Deferred Revenue
171.80MUSDFY2025 · Dec 31, 2025Other Current Liabilities
127.70MUSDFY2025 · Dec 31, 2025Long-term Debt
1.95BUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
267.40MUSDFY2025 · Dec 31, 2025Common Stock (Book)
2.50MUSDFY2025 · Dec 31, 2025Retained Earnings
13.56BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
18.67BUSDvs all stocks (USD)
52-Week Low
362.50USDUpdated Jul 19, 202652-Week High
533.67USDUpdated Jul 19, 202652-Week Change
5.92%vs all stocks
Beta
0.2920xvs all stocks
50-Day MA
459.91USDUpdated Jul 19, 2026200-Day MA
449.31USDUpdated Jul 19, 2026Avg 10-Day Volume
1.60MSharesUpdated Jul 19, 2026Avg 30-Day Volume
1.79MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
16.85USDUpdated Jul 19, 2026Other Income / Expense
-388.80MUSDFY2025 · Dec 31, 20259 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Is this company growing?
Revenue Growth With Elevated Margin
Revenue up in each of five years, while its operating margin stays high.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Profit margin is 35.5%, higher than 95% of its Biotechnology peers (median 6%)Significant
Profit margin: 0.36Industry median: 0.06Industry P95: 0.34Peers compared: 24.00
Financial Health
Altman Z-Score 12.75: safe zoneNotable
Altman Z-Score: 12.75
High structural barrier to entryNotable
Barrier to Entry: 0.55
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $123.26B, higher than 95% of all stocks globallySignificant
Market cap (USD): 123,260,598,227Global P95: 25,614,208,870.135
Levered free cash flow is $2.78B, higher than 95% of all stocks globallySignificant
Levered free cash flow (USD): 2,783,225,088Global P95: 1,123,592,359.78
Revenue is $12.22B, above the global median of $520.53MNotable
Revenue (USD): 12,218,000,384Global Median: 520,528,949.311
Companies that share the same coordination system — how they create, deliver, or capture value.
Stryker Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Bristol-Myers Squibb Company
Tier 1ProductionApproval-Gated PipelineRuleFlow
Medtronic plc
Tier 1ProductionApproval-Gated PipelineRule
Pfizer Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
GSK plc
Tier 1ProductionApproval-Gated PipelineRuleFlow
Novo Nordisk A/S
Tier 1ProductionApproval-Gated PipelineRule
Gilead Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Abbott Laboratories
Tier 1ProductionApproval-Gated PipelineRuleFlow
Amgen Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Regeneron Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
United States Lime & Minerals Inc.
9 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels
Catalyst Pharmaceuticals Inc.
9 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels
Euroseas Ltd.
9 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels